Ncardia and Bluerock Therapeutics announce collaboration agreement and licensing of process development technologies for the manufacture of iPSC-derived cardiomyocytes

Ncardia and BlueRock Therapeutics today announced an agreement covering process development technologies for the manufacture of induced pluripotent stem cell (iPSC)-derived cardiomyocytes.
Read More